Kornimate/medical-research-clean huggingface dataset:
effects of providing preprint preoperative anesthetic risk information

Conditions: Preoperative Anxiety

Summary: proportion of patients in study group(preprint preoperative anesthetic risk should have more anxiety, more knowledge, and more cancellation than controlled group


Eligibility criteria:
inclusion criteria: * inpatients scheduled for surgery under general anesthesia with or without regional anesthesia * low to moderate risk surgery exclusion criteria: * patient's refusal * patients scheduled for cardiovascular surgery and neurosurgery * patients with consciousness change following surgery * emergency case * cns or psychological diseases

Keywords: anxiety preprint anesthetic risk information
sleep, pain and inflammatory processes in older adults with osteoarthritis

Conditions: Osteoarthritis of the Knee; Insomnia; Knee Pain

Summary: the purpose if the study is to determine whether improving sleep, especially slow wave or "deep" sleep, in older adults with osteoarthritis (oa) and insomnia reduces pain sensitivity and inflammatory responses to pain, and improves oa-related pain.


Eligibility criteria:
inclusion criteria: * 50-75 years of age (for women, post-menopausal) * kellgren-lawrence grade ii radiographic evidence of oa affecting one or both knees * knee pain on most days for ≥ 6 months * self-reported disability due to knee pain for ≥ 2 of the following: walking, kneeling, ascending or descending stairs, or performing daily activities * willing and able to avoid all prescription and non-prescription, non-opiate pain medication for 48 hours prior to testing and all narcotic pain medication for 2 weeks prior to testing * meets research diagnostic criteria for sleep maintenance insomnia exclusion criteria: * health conditions with immunological components or undergoing or taking immunosuppressive therapies * conditions contraindicated for or potentially limiting ability to conduct nfr and/or cold pressor test (e.g. raynaud's syndrome; seizures; prior mi; respiratory conditions; leg/hip nerve damage; bmi ≥ 32) * sleep disorders other than insomnia * dementia or cognitive impairment * history of schizophrenia or bipolar i disorder; current or recent history (within 3 months) of major psychiatric disorders * current depressive symptomatology or current suicidality * active substance dependence * untreated hypertension * use of antidepressants (stable use for 3 months okay), antipsychotics, mood stabilizers, sedative-hypnotics, opiate analgesics

Keywords: osteoarthritis insomnia chronic pain cognitive behavioral therapy for insomnia inflammation inflammatory cytokines
evaluation of nutritional status in thalassemia major patients in assiut children hospital

Conditions: Thalassemia Major

Summary: thalassemia is a blood disorder passed down through families in which the body makes an abnormal form of hemoglobin. there are 2 main types of thalassemia; alpha \& beta thalassemia. alpha thalassemia: occurs when a gene or genes related to the alpha globin protein are missing or mutated. beta-thalassemia syndromes are a group of hereditary blood disorders characterized by reduced or absent beta globin chain synthesis. beta-thalassemias can be classified into: silent carrier: completely asymptomatic with normal hematological parameters. beta-thalassaemia minor (beta-thalassaemia trait): usually asymptomatic; diagnosis is made during a work-up for mild anemia. beta-thalassaemia intermedia: usually a similar presentation to beta-thalassaemia major; symptoms are usually less pronounced and the course is usually more insidious. beta-thalassaemia major : in which there is complete absence of hemoglobin a

in egypt beta thalassemia-major is the most common type with carrier rate of 5.3 to ≥9%and 1000 new cases born with beta-thalassemia major per 1.5 million live births per year. children born with thalassemia major are normal at birth, but develop severe hemolytic anemia during the first year of life. symptoms are those of anemia (lethargy, poor feeding, pallor...etc.) failure to thrive and organomegaly. later on they develop signs of extra medullary hematopoiesis . optimal nutritional status is important for growth, immune function, bone health and pubertal development . various reports suggest the incidence of poor growth ranges from 25% to 75% depending on thalassemia syndrome and severity of disease. this marked growth deficits raise a red ﬂag for any pediatrician to evaluate nutritional status of thalassemic patients and detect possible nutritional deficiencies and associated factors. etiology of delayed growth and malnutrition reported in thalassemic patient is multifactorial including : 1. nutritional deprivation with or without feeding difficulties arising from fatigue and breathlessness 2. increased energy expenditure secondary to hyper metabolism with or without heart failure 3. gastrointestinal hypoxia which consequently produces anorexia and malabsorption 4. reduction of biosynthetic activity of liver. 5. disturbance of the endocrine function 6. impaired synthetic hepatic function secondary to hemosiderosis and hepatitis. the main aim of this study is to assess the nutritional status of thalassemic patient attending assiut university children hospital and to determine the factors involved.

Eligibility criteria:
inclusion criteria: * patients diagnosed to have thalassemia exclusion criteria: * patient with any underlaying systemic diseases other than b thalassemia major.

Keywords: thalassemia - nutrition -growth
iv amiodarone versus iv procainamide to treat haemodynamically well tolerated ventricular tachycardia

Conditions: Ventricular Tachycardia; Wide QRS Tachycardia

Summary: the purpose of this study is to determine whether intravenous amiodarone has less cardiac significant adverse events compared to intravenous procainamide in the acute treatment of haemodynamically well tolerated wide qrs tachycardia, the majority of them of probably ventricular origen.

multicenter, prospective and randomized study in phase iv. a total of 302 patients will be included in the study within 40-50 institutions in spain. patients with regular and monomorphic tachycardia ≥ 120 bpm, qrs ≥ 120 ms and haemodynamically well tolerated will be randomized to receive iv amiodarone (single dosage: 5 mg/kg in 20 minutes) vs iv procainamide (single dosage: 10 mg/kg in 20 minutes). the study period will be 40 minutes from infusion initiation. study variables include the presence of clinically cardiac significant adverse events: hypotension, syncope, heart failure, symptomatic sinus bradycardia, av block, proarrhythmia and tachycardia acceleration (\<20 lpm)and death. total observation period will be 24 hours after the end of the infusion.

Eligibility criteria:
inclusion criteria: * patients with stable tachycardia ≥120 lpm, qrs ≥120 ms and haemodynamically well tolerated defined as: 1)systolic blood pressure ≥90 mmhg, 2) absence of dyspnea at rest, 3)absence of peripheric hypoperfusion signs and 4)no severe angina. * age \> 18 years * written inform consent obtained exclusion criteria: * treatment with iv amiodarone or iv procainamide during the previous 24 hours * qrs tachycardia \<120 ms * patients with qrs ≥120 ms tachycardia with haemodynamic compromise that requires urgent cardioversion for termination * irregular tachycardia * tachycardia that is considered as supraventricular due to physician criteria (adenosine and/or vagal manoeuvres response) * patient that do not want to cooperate

Keywords: ventricular tachycardia
effect of bariatric surgery "digestive adaptations iii" on cardiovascular risk

Conditions: Diabetes Mellitus; Metabolic Syndrome; Obesity; Atherosclerosis

Summary: introduction- primary prevention is the main strategy to control the global burden of cardiovascular disease. in clinical practice, food restriction represents a valuable preventive resource. however, low adhesion rates and diet abandonment are considered important obstacles in treatment. considering the discovery of new markers and mechanisms that relate food restriction and to all other cardiovascular risk factors, it is possible and necessary to seek for efficient alternatives to increase adherence and effectiveness of the preventive dietetic treatment. surgical procedures can be used as a mechanism to promote food restriction. the bariatric surgery have gained importance not only for its potential application in obesity treatment but also in the control of cardiovascular risk factors refractory to medical treatment. among bariatric operations, there is a group called digestive adaptations iii that has specific characteristics.this surgical intervention modifies intestinal tract by reducing gastric volume and performing an anastomosis between ileum and stomach, creating a bipartition in the gut. this structural modification promotes satiety and increased insulin sensitivity more intensely than other surgical strategies. the effects of digestive adaptation iii surgery on cardiovascular risk factors and on markers related to the development of atherosclerosis are not yet established. objectives - to investigate the effect of digestive adaptation iii surgery on clinical and laboratory parameters and cardiovascular risk factors. methods - twenty diabetics volunteers refractory to medical treatment and who have abdominal obesity will be included in the study. of this group, half will be randomly selected to perform the digestive adaptations iii surgery. all participants will undergo clinical and biochemical tests on the same occasions, up to thirty days before surgery, three twenty-four months after surgery. on these occasions besides the lipid profile and glucose, we will determine incretin hormones, adipokines and assess the amount of epicardial fat.


Eligibility criteria:
inclusion criteria: * men. * adults (raging from 18 to 65 years). * ability to understand the procedure, risks and alternatives. * patients with bmi \> 28 kg/m2 and \< 35 kg/m2 presenting type 2 diabetes diagnosed for more than two years and less than 10 years. * glycated hemoglobin\> 8% despite dietary and medical treatment that already includes the use of exogenous insulin * waist circumference \> 102 cm. exclusion criteria: * chronic diseases not related to severe obesity. * pregnancy. * peptide c \<1.5 ng / ml or a positive anti-islet antibodies, anti-gad or anti-ica512. * previous cancer, unless deemed cured (after 5 years of treatment, at least) * acute infection or chronic relevant. * alcohol addiction. * tobacco use. * drug addiction, except those recovered for more than three years.

Keywords: atherosclerosis cardiovascular risk factors calorie restriction bariatric surgery
brief binge eating and drinking online intervention

Conditions: Binge Eating; Binge Drinking

Summary: this pilot project targets both binge drinking and binge eating behavior in college students through a mobile-based online program that provides students with evidence-based intervention material designed to reduce the incidence of both behaviors and encourage students to seek more formal in-person counseling.

despite the prevalence of binge drinking and binge eating behaviors among college students, few students seek care for either. intervening with college students early is essential as untreated symptoms of binge drinking and binge eating behaviors can become more severe and persistent over time, often leading to diagnosed disorders and lasting consequences on students' social functioning, physical health, and educational attainment. thus, the major goal of this research study is to target both binge drinking and binge eating behavior in college students through a mobile-based online program that provides students with evidence-based intervention material designed to reduce the incidence of both behaviors, as well as encourage students to seek more formal in-person counseling. the intervention combines two innovations to facilitate behavior change: (1) personalized drinking and binge eating intervention content with harm reduction and cognitive behavioral skills proven to be efficacious in reducing these problematic behaviors among college students delivered via (2) a mobile-based program that increases accessibility, is easy and engaging to use, and broadens the accessibility of the intervention content to an often non-treatment seeking group. the intervention is informed by evidence-based practices, with student and expert feedback, to help limit alcohol consumption, engage in healthier eating behaviors, and practice alternate strategies to manage negative affect.

Eligibility criteria:
inclusion criteria: * full time undergraduate student at the study site * between the ages of 18 and 24 * ability to speak and read english * at least two occasions of binge drinking (5 or more drinks in a row for males, 4 (i.e., an objectively large amount of food with a self-reported loss of control) in the past 28 days * at least two occasions of binge eating (i.e., an objectively large amount of food with a self-reported loss of control)151 in the past 28 days * no receipt of mental health or substance use care in the past month. exclusion criteria: * not meeting eligibility criteria
first-in-human study of adce-d01 in soft tissue sarcoma

Conditions: Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma

Summary: the goal of this clinical trial is to learn about the safety, tolerability and efficacy of adce-d01.

safety and tolerability evaluated by incidence of dlts. efficacy evaluated by antitumor activity; orr, dor, pfs, cbr and ttr per recist v i.1.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. histologically confirmed sts with metastatic and/or unresectable disease (not amenable to treatment with curative intent). 3. prior treatment with at least one but no more than two lines of cytotoxic systemic therapy for metastatic/unresectable disease. 4. measurable disease as per recist v 1.1. 5. eastern cooperative oncology group (ecog) performance status of 0 or 1. 6. life expectancy of at least 3 months. 7. a male patient must agree to use barrier contraception during the treatment period and for at least 4 months after the last infusion of study treatment, and refrain from donating sperm during this period. male patients with a pregnant partner must practice sexual abstinence or use a barrier method of contraception (e.g., condom) to prevent exposure of the fetus or neonate. 8. a female patient is eligible if not pregnant, not breast feeding, and not a woman of childbearing potential (wocbp), or agrees to follow the contraceptive guidance during the treatment period and for at least 7 months after last infusion of study treatment. exclusion criteria: 1. patients who have had systemic anticancer therapy, including any investigational agent within 4 weeks or 5 half-lives (whichever is shorter) prior to study treatment administration. 2. primary brain malignancy or known, untreated central nervous system (cns) or leptomeningeal metastases, or symptoms suggesting cns involvement. 3. clinically significant cardiovascular disease 4. patients with acute infection with human immunodeficiency virus (hiv) 1 or hiv 2. 5. current active liver disease due to hepatitis b 6. history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on a chest computed tomography (ct) scan at screening.

Keywords: phase 1/phase 2 sequential treatment
ahmed valve glaucoma implant with adjunctive subconjunctival bevacizumab in refractory glaucoma

Conditions: Refractory Glaucoma

Summary: the investigators aim to demonstrate the efficacy and safety of subconjunctival injection of avastin as an adjunctive therapy for ahmed valve glaucoma implant in patients with refractory glaucoma.

several studies have revealed evidences on the substantial role of vascular endothelial growth factor-a (vegf-a) in enhancing neovascularization processes. some studies have shown the efficacy of intravitreal avastin in reducing level of vegf-a to improve nvg. on the other hand, recent pathological studies demonstrated that neutralization of vegf reduced vascularity and decreased scar formation during wound healing, showing that vegf strongly influence scar tissue formation. this may reduce the formation of encapsulated cyst after glaucoma surgeries and thus might improve the surgical success rate. the effect of subconjunctival bevacizumab as an adjunctive therapy in filtering glaucoma surgeries has been recently illustrated. we aim to demonstrate the efficacy and safety of subconjunctival injection of avastin as an adjunctive therapy for ahmed valve glaucoma implant in patients with refractory glaucoma.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of refractory glaucoma defined as uncontrolled iop (\> 21 mm hg) despite maximal antiglaucoma medication, previously failed surgical treatment, or a combination thereof exclusion criteria: * no light perception * elevated iop associated with silicone oil * previous glaucoma drainage device implantation in the same eye * previous cyclodestructive treatment * increased risk of endophthalmitis (e.g., active adnexal and ocular surface infection, immunosuppression, or immunodeficiency, including the use of systemic steroids) * posterior segment disorders, or pre-existing ocular comorbidities (e.g., pterygium, phacodonesis, corneal opacity, or corneal endothelial dystrophies). only 1 eye per patient was included in this trial.

Keywords: ahmed valve neovascular glaucoma uveitic glaucoma failed glaucoma vegf-a intraocular pressure subconjunctival avastin
a study to evaluate the effect of hepatic impairment on jnj-56136379

Conditions: Hepatic Impairment

Summary: the purpose of the study is to evaluate the pharmacokinetics (pk) of a single oral dose of jnj-56136379 in participants with liver cirrhosis and impaired hepatic function when compared with healthy participants with normal hepatic function and no liver cirrhosis.


Eligibility criteria:
inclusion criteria: * for all participants: body mass index (bmi) between 18.0 and 38 kilogram per meter square (kg/m2), extremes included; woman of childbearing potential must not be pregnant; highly effective contraceptive measures in place for female participants of childbearing potential or male participants with female partners of childbearing potential; non-smoker or light smoker as defined per protocol. * for healthy participants with normal hepatic function and no liver cirrhosis: demographically comparable to the study groups with hepatic impairment with respect to sex, age (+/-10 years), and body weight (+/-10 kilogram \[kg\]); participants must be in good health clinically and biologically as defined per protocol. * for participants with liver cirrhosis and moderate or mild or severe hepatic impairment: must have a total child-pugh score of 5 or 6, inclusive (mild); or 7 to 9, inclusive (moderate); or 10 to 15, inclusive (severe) as determined by the investigator; must have liver cirrhosis with fibro scan readout greater than (\>) 12.5 kilopascal (kpa) as cut-off at screening * participants with controlled hypertension, with problems directly associated with the primary diagnosis of hepatic impairment and with concurrent stable medical conditions if the condition(s) will not introduce an additional risk factor and will not interfere with the study objectives. * concomitant medications to treat underlying disease states or medical conditions related to hepatic impairment are allowed. exclusion criteria: * history of / or current clinically significant medical illness that could interfere with the interpretation of the study results. * known allergies, hypersensitivity, or intolerance to jnj-6379 or its excipients. * history of drug or alcohol abuse within 1 year before screening or positive test results at screening and day -1. * blood or blood products donated or substantial loss of blood (more than 500 milliliters \[ml\]) within 3 months before the study starts * experimental drug received (including investigational vaccines) or experimental medical device used within 1 month or within a period less than 10 times the drug's half-life, whichever is longer, before the first dose of the study intervention is scheduled. * evidence of infection with human immunodeficiency virus (hiv)-1 and hiv-2, hepatitis a, b or c (except if sustained virologic response to hepatitis c virus \[hcv\] treatment). * inability to fast for 10 hours. * signs of hepatocellular carcinoma or history of biliary obstruction within the past 2 years. * lack of good or reasonable venous access.
a phase 1, single dose study of jzp-386 to evaluate safety, pharmacokinetics and pharmacodynamics

Conditions: Narcolepsy, Excessive Daytime Sleepiness

Summary: this study is being conducted to evaluate the safety, tolerability, blood distribution and effectiveness single ascending doses of jzp-386 compared to doses of xyrem® and placebo.

this is a phase 1, single center, single-ascending dose, sequential, randomized, and crossover study. following a screening period of up to 21 days, eligible subjects will be randomized different dosing sequences, with approximately 4 subjects allocated to each dosing sequence. the total in-clinic duration for each subject will be 24 days (including the admission day prior to the first dosing period).

Eligibility criteria:
inclusion criteria: * healthy male and female volunteer subjects, 18 to 50 years of age, inclusive. exclusion criteria: clinically significant history of unstable medical abnormality. inability to cooperate with study procedures. female subjects with a positive pregnancy test result, nursing or lactating. participation in any other investigational drug trial within 90 days prior to screening. a history of prescription drug abuse, or illicit drug or known drug dependence within last 5 years prior to screening. use of any prescription medication within 14 days prior to dosing. a history of alcohol abuse or dependence.

Keywords: jzp-386, xyrem, sodium oxybate
investigating consumers perception and acceptance of whey beverages

Conditions: Individual Difference; Food Sensitivity; Food Preferences

Summary: brief summary: this study aims to investigate whether protein fortification of beverages causes mouthdrying and mucoadhesion and whether this is influenced by saliva flow.

to investigate whether whey protein beverages causes mouthdrying and reduces acceptability compared with a control beverage (whey permeate beverage) and to determine whether manipulating salivary flow rates influences mouthdrying. to determine whether mucoadhesion is a probable cause of mouthdrying.

Eligibility criteria:
inclusion criteria: * healthy * no food allergies or intolerances * non smokers exclusion criteria: * taking prescribed medication that could influence study outcomes (such as saliva flow) * relevant food allergies or intolerances * outside age criteria * cancer * had oral surgery or a stroke * smoker * diabetic * anyone who currently has covid-19 symptoms or who has had covid-19 within the last 4 weeks

Keywords: mouthdrying saliva flow mucoadhesion oral nutritional supplements
interfaces of non-invasive ventilation on performance in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Non Invasive Ventilation; Exercise, Aerobic

Summary: the purpose of this study is to determine wether the interface (facial or nasal mask) influences performance in patients with chronic obstructive pulmonary disease exercising with non-invasive ventilation.


Eligibility criteria:
inclusion criteria: * age \> 18 years * chronic obstructive pulmonary disease gold iii-iv * eligible for pulmonary rehabilitation * exercise limitation : at least respiratory limitation (ventilatory reserve ≤ 30%) non-inclusion criteria: * pregnant woman or likely to be * familiar with home non-invasive ventilation * patient under guardianship exclusion criteria: * acute exacerbation of chronic obstructive pulmonary disease